Notice of Results

Abingdon Health PLC

05 March 2026

 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

Notice of Results

Investor Presentation

York, U.K. 5 March 2026: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, will announce its interim results for the six months ended 31 December 2025 on Tuesday 17 March 2026.

Investor Presentation

The Company will provide a live online presentation relating to the interim results via the Investor Meet Company platform on Tuesday 17 March 2026 at 11:00 GMT. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 09:00 GMT the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Abingdon Health plc via: https://www.investormeetcompany.com/abingdon-health-plc/register-investor

Investors who already follow Abingdon Health plc on the Investor Meet Company platform will automatically be invited.

Enquiries:

Abingdon Health plc	www.abingdonhealth.com/investors/
Chris Hand, Executive Chairman		Via Walbrook PR
Tom Hayes, CFO
Cavendish Capital Markets Limited (Sole Broker and Nominated Adviser)		Tel: [phone]
Geoff Nash / Isaac Hooper / Joe Smith (Corporate Finance) Nigel Birks (Life Science Specialist Sales)
Walbrook PR (Media & Investor Relations)	Tel: [phone] or [e-mail]
Paul McManus / Alice Woodings	Mob: [phone]

About Abingdon Health

Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.   

The Group's CDMO (Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success. 

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK.  Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.   The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities. 

Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.

Abingdon Health's brochure outlines the comprehensive support the Group can now provide to its international customers.  For more information visit: www.abingdonhealth.com.

 

END